Tag: beigene

January 15, 2019

BeiGene Receives U.S. FDA Breakthrough Therapy Designation for Zanubrutinib

BeiGene (NASDAQ:BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the...
December 20, 2018

5 Top Biotech and Pharma Stocks on the TSX Year-to-Date

Which biotech and pharma stocks on the TSX have performed the best in 2018? Here's a look at the top...
November 27, 2018

Zymeworks and BeiGene Announce License and Collaboration Agreement

Zymeworks (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, and BeiGene (Nasdaq: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company...
October 24, 2018

BeiGene Announces Acceptance of its New Drug Application in China and Top-Line Pivotal Data for Zanubrutinib

BeiGene (NASDAQ:BGNE;HKEX:06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of...
October 10, 2018

BeiGene Announces National Reimbursement Inclusion of VIDAZA by the State Medical Insurance Administration in China

BeiGene (NASDAQ:BGNE; HKEX:06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of...
August 31, 2018

BeiGene Announces Acceptance of New Drug Application for Anti-PD-1 Antibody Tislelizumab in Hodgkin’s Lymphoma in China

BeiGene (NASDAQ:BGNE; HKEX:06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment...
August 9, 2018

BeiGene Announces Closing of Its HK$7.08 billion (US$903 million) Hong Kong Initial Public Offering and Global Offering

BeiGene (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of...